Resources Repository
-
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Cost-Effectiveness Analysis | Health Outcomes | Chronic Disease/Risk | Preferences/Values | Decision Analysis | Health Systems | Economics/Finance | Health/Medicine | North America | Europe -
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Costing Methods | Technology Assessment | Child/Nutrition | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Food/Agriculture | Health/Medicine | Latin America & Caribbean -
ReviewPublication 2016Strengthening Cost-Effectiveness Analysis for Public Health Policy
Many important opportunities to improve health lie outside the health sector and involve improving the …
Many important opportunities to improve health lie outside the health sector and involve improving the conditions in which we live and work: safe design and maintenance of roads, bridges, train tracks, and airports; control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food supply; safe manufacture of consumer products; a healthy social environment; and others. Faced with the overwhelming array of possibilities, U.S. decision makers need help identifying those that can contribute the…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Environmental Health | Preferences/Values | Costing Methods | Social Determinants | Health Systems | Policy/Regulation | Climate/Environment | Economics/Finance | Food/Agriculture | Health/Medicine | North America -
ReviewPublication 2016Review: CEA for Maternal, Newborn, Child Health
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions …
This chapter summarizes the findings of a systematic search of the cost-effectiveness literature on interventions to improve reproductive, maternal, newborn, and child health. Interventions for newborn health, treatment of febrile illness, immunization against preventable diseases, and micronutrient interventions remain among the most cost-effective and affordable. Other studies explore how to provide existing interventions using new platforms to increase outreach or decrease cost per person covered, or both. Interventions provided in the community may achieve both purposes to…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Costing Methods | Infectious Diseases | Child/Nutrition | Health Systems | Education/Labor | Health/Medicine | Global -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Chronic Disease/Risk | Technology Assessment | Infectious Diseases | Child/Nutrition | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | North America -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ReviewPublication 2023Modelling the Cost Effectiveness of Treatments for Parkinson's Disease: Methodological Review
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms …
This article systematically reviewed the methodological quality of economic evaluation models for treating motor symptoms in Parkinson’s disease in studies published post-2010. Methods included a systematic literature search using databases such as PubMed, EconLit, Cochrane, and several UK National Health Service databases, covering March 2010 to July 2022. The quality of the identified studies was assessed using a checklist from the German Scientific Working Group. Results showed that 20 studies were evaluated, most employing Markov…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Evidence Synthesis | Health/Medicine -
ReviewPublication 2023Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: Systematic Review
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) …
This systematic review assesses the cost-effectiveness of recent early detection strategies for cardiovascular disease (CVD) in at-risk adult populations. Methods included searching PubMed and Scopus for articles published between January 2016 and May 2022. The first reviewer screened all articles, while a second reviewer independently validated a random 10% sample. Discrepancies were resolved through discussion, with a third reviewer involved if necessary. Costs were standardized to 2021 euros. Reporting quality was evaluated using the CHEERS…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Evidence Synthesis | Health/Medicine -
ReviewPublication 2023Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic …
This systematic review analyzed cost-effectiveness analyses (CEAs) using decision-analytical modeling (DAM) to compare non-insulin antidiabetic drugs (NIADs) within glucagon-like peptide-1 (GLP1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors for treating type 2 diabetes mellitus (T2DM). The study focused on economic results and underlying methodological choices. Methods included searching PubMed, Embase, and Econlit databases from January 1, 2018, to November 15, 2022. Two reviewers screened titles, abstracts, and full texts for relevance…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Evidence Synthesis | Mathematical Models | Health/Medicine | Europe